CN113271968B - 经修饰的巨细胞病毒蛋白和稳定化的复合物 - Google Patents

经修饰的巨细胞病毒蛋白和稳定化的复合物 Download PDF

Info

Publication number
CN113271968B
CN113271968B CN201980084001.XA CN201980084001A CN113271968B CN 113271968 B CN113271968 B CN 113271968B CN 201980084001 A CN201980084001 A CN 201980084001A CN 113271968 B CN113271968 B CN 113271968B
Authority
CN
China
Prior art keywords
complex
hcmv
seq
polypeptide
residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980084001.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113271968A (zh
Inventor
E·马利托
M·J·博顿利
A·卡菲
S·钱德拉莫里
K·路易西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN113271968A publication Critical patent/CN113271968A/zh
Application granted granted Critical
Publication of CN113271968B publication Critical patent/CN113271968B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/045—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980084001.XA 2018-10-17 2019-10-15 经修饰的巨细胞病毒蛋白和稳定化的复合物 Active CN113271968B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746804P 2018-10-17 2018-10-17
US62/746804 2018-10-17
PCT/IB2019/058777 WO2020079586A1 (en) 2018-10-17 2019-10-15 Modified cytomegalovirus proteins and stabilized complexes

Publications (2)

Publication Number Publication Date
CN113271968A CN113271968A (zh) 2021-08-17
CN113271968B true CN113271968B (zh) 2024-06-14

Family

ID=68296588

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980084001.XA Active CN113271968B (zh) 2018-10-17 2019-10-15 经修饰的巨细胞病毒蛋白和稳定化的复合物

Country Status (8)

Country Link
US (2) US11932669B2 (https=)
EP (1) EP3866845A1 (https=)
JP (1) JP7584405B2 (https=)
CN (1) CN113271968B (https=)
BR (1) BR112021006812A2 (https=)
CA (1) CA3116175A1 (https=)
MX (1) MX2021004273A (https=)
WO (1) WO2020079586A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021245611A1 (en) 2020-06-05 2021-12-09 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
JP2023553854A (ja) 2020-12-02 2023-12-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ドナー鎖補完性ｆｉｍｈ
EP4526327A1 (en) * 2022-05-20 2025-03-26 GlaxoSmithKline Biologicals S.A. Modified varicella zoster virus glycoprotein e proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181142A1 (en) * 2014-05-27 2015-12-03 Glaxosmithkline Biologicals S.A. Cytomegalovirus complexes and uses thereof
CN107531761A (zh) * 2015-01-22 2018-01-02 葛兰素史密丝克莱恩生物有限公司 巨细胞病毒抗原及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388186A1 (en) 1989-03-17 1990-09-19 E.I. Du Pont De Nemours And Company External regulation of gene expression
US5362865A (en) 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
HK1046911A1 (zh) 1999-06-25 2003-01-30 Progenics Pharmaceuticals, Inc. 经稳定的病毒外膜蛋白质及其使用
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
DK2352759T3 (en) 2008-07-16 2017-12-18 Inst Res Biomedicine ANTIBODIES THAT NEUTRALIZE HUMAN CYTOMEGALOVIRUS AND USE THEREOF
EP2320945A4 (en) 2008-07-30 2013-02-27 Emergent Biosolutions Inc STABLE MILZBRANDIMPFSTOFFFORMULIERUNGEN
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
CA2885145A1 (en) 2012-10-30 2014-05-08 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
JP6818551B2 (ja) * 2013-12-03 2021-01-20 ホオキパ バイオテック ジーエムビーエイチ Ｃｍｖワクチン
MX2016014660A (es) 2014-05-08 2017-02-28 Pfizer Medios y metodos para el tratamiento de cmv.
AU2016342045A1 (en) * 2015-10-22 2018-06-07 Modernatx, Inc. Human cytomegalovirus vaccine
EP3600397A4 (en) * 2017-03-28 2021-01-27 Children's Hospital Medical Center NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015181142A1 (en) * 2014-05-27 2015-12-03 Glaxosmithkline Biologicals S.A. Cytomegalovirus complexes and uses thereof
CN107531761A (zh) * 2015-01-22 2018-01-02 葛兰素史密丝克莱恩生物有限公司 巨细胞病毒抗原及其用途

Also Published As

Publication number Publication date
CN113271968A (zh) 2021-08-17
US20210277067A1 (en) 2021-09-09
US12384819B2 (en) 2025-08-12
US20240383949A1 (en) 2024-11-21
JP2022505094A (ja) 2022-01-14
US11932669B2 (en) 2024-03-19
EP3866845A1 (en) 2021-08-25
JP7584405B2 (ja) 2024-11-15
MX2021004273A (es) 2021-12-10
WO2020079586A1 (en) 2020-04-23
WO2020079586A9 (en) 2021-05-06
BR112021006812A2 (pt) 2021-07-20
CA3116175A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
US12384819B2 (en) Modified cytomegalovirus proteins and stabilized complexes
JP7770382B2 (ja) ヒトサイトメガロウイルスｇｂポリペプチド
US20250009874A1 (en) Modified cytomegalovirus proteins and stabilized complexes
US20240189416A1 (en) Stabilized coronavirus spike protein fusion proteins
WO2025236842A1 (zh) 一种vzv重组蛋白及其制备方法和应用
WO2025241209A1 (zh) Rsv融合前f蛋白的突变体及其制备和应用
AU2016313660B2 (en) Polypeptide carrier for presenting target polypeptide and uses thereof
HK40024599A (en) Modified cytomegalovirus proteins and stabilized complexes
WO2016141201A2 (en) Rational vaccine design for hepatitis c virus
HK40112146A (zh) Rsv融合前f蛋白的突变体及其制备和应用
HK40112146B (zh) Rsv融合前f蛋白的突变体及其制备和应用
EA046906B1 (ru) Вакцины против вируса гриппа и пути их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant